Article Archives

Global Hidradenitis Suppurativa Atlas Launches Report to Advance Awareness and Knowledge on HS

The Global Hidradenitis Suppurativa Atlas (GHiSA), an international non-profit organization, has produced its first report on Hidradenitis Suppurativa (HS). This comprehensive overview of HS was produced with the International League

Empowering Clinicians: Essential HS Resources for Hidradenitis Suppurativa Week

As health care providers, staying informed and having access to the latest information on Hidradenitis Suppurativa (HS) is crucial to ensuring you provide optimal care to your patients with this

Reflecting on AAPI Heritage Month: Advancing Culturally Competent Dermatological Care for the AAPI Community

As we close out the month of May and Asian American and Pacific Islander Heritage Month, it seems an opportune time to reflect on providing culturally competent and equitable dermatological

Concerning Gaps in Existing AI Dermatology Apps

A review recently published in JAMA Dermatology analyzed the current state of artificial intelligence (AI) dermatology mobile applications (apps), looking specifically at their purpose, supporting evidence, regulatory status, clinician input,

Erenumab May Help Reduce Erythema in Rosacea

Rosacea, a common facial skin disease, is estimated to affect over 16 million Americans. According to the National Rosacea Society, “Rosacea may develop in many ways and at any age,

A Review of Cosmetic Injectable in Skin of Color Patients

A recent study reviewed the use of cosmetic injectables in individuals with skin of color (S0C) with the aim of assessing their uses, effectiveness, and safety. SoC populations are increasingly

Andrew Alexis Honored at Second Annual Fleur De Cure Event

Andrew F. Alexis, MD, MPH, was recently honored at the second annual Fleur De Cure event in New York City. This special gathering, organized by the National Psoriasis Foundation and

FDA Warns of Counterfeit Botox Products

The U.S. Food and Drug Administration (FDA) has issued a warning to all health care professionals and consumers revealing that counterfeit versions of Botox (botulinum toxin) have been uncovered in

FDA Approves Supplemental Biologics License Application for BIMZELX for Hidradenitis Suppurativa

Global biopharmaceutical company, UCB, recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BIMZELX® (bimekizumab-bkzx) for the treatment

FDA Warns Consumers Not to Use Certain Topical OTC Pain Relief Products

The U.S. Food and Drug Administration (FDA) has issued a warning to consumers to not use certain over-the-counter (OTC) pain relief products due to the potential for dangerous health effects.

New Study Reveals – Patients with Plaque Psoriasis Treated with JNJ-2113 Maintain Skin Clearance Up to One Year

Johnson & Johnson recently announced the first data from their FRONTIER 2 clinical trial which evaluated JNJ-2113. This is the first and only investigational targeted oral peptide designed to block

Pediatric Morphea Disease Progression Predicted by Multispectral Imaging

A recent study revealed that multispectral imaging could provide promising accuracy when predicting the progression of pediatric morphea. Morphea, also known as localized scleroderma, is described as “an inflammatory, fibrosing

Advice and Guidance for Dermatologists for BPO-Containing Products from Dr. Christopher Bunick

Recent revelations about the presence of benzene in benzoyl peroxide (BPO)-containing acne products have put dermatologists in a challenging position. Patients are understandably concerned about the safety of their acne

BREAKING NEWS: Dangerous Benzene Found in Acne Products-Citizens Petition Filed with FDA

In recent breaking news, concerns surrounding benzene contamination have resurfaced, sparking renewed health worries and heightened regulatory scrutiny. Valisure LLC, an independent laboratory facility, has revealed the results of its

Oral IL-23 Receptor Antagonist Peptide Shows Promising Results for Plaque Psoriasis

JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be

Intravenous Ertapenem Therapy Associated with Improvement in Hidradenitis Suppurativa

Findings from a recent analysis have revealed that the administration of intravenous ertapenem demonstrates improvement in clinical and inflammatory markers of hidradenitis suppurativa (HS) in addition to improved patient satisfaction.

Spotlight on South Beach Symposium and Masters of Pediatric Dermatology Symposium

LiVDerm’s annual South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) Symposium recently concluded after an impactful few days of dermatology education. Healio was on site, providing coverage of

Dupilumap and Topical Corticosteroids Can Help Alleviate Symptoms of AD in Children

According to a recent study published in the Journal of Immunity, Inflammation, and Disease, combining topical corticosteroids with dupilumab can significantly help alleviate symptoms associated with atopic dermatitis (AD) in

Using A 20% Urea Moisturizer May Improve Skin’s Smoothness and Texture in Keratosis Pilaris

A recent study evaluated the effects of a moisturizer containing 20% urea on patients with keratosis pilaris (KP) and found that it may help to improve the skin’s smoothness and

Galderma Announces Positive Results from their Phase 3 Study of RelabotulinumtoxinA

In a recent press release, Galderma announced that RelabotulinumtoxinA significantly improved glabellar and lateral canthal lines. Data from their Phase III READY-3 clinical trial reveal that a single dose of

LivDerm Articles

Latest Articles

Explore Articles